alendronate has been researched along with Neurofibromatosis 1 in 2 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Neurofibromatosis 1: An autosomal dominant inherited disorder (with a high frequency of spontaneous mutations) that features developmental changes in the nervous system, muscles, bones, and skin, most notably in tissue derived from the embryonic NEURAL CREST. Multiple hyperpigmented skin lesions and subcutaneous tumors are the hallmark of this disease. Peripheral and central nervous system neoplasms occur frequently, especially OPTIC NERVE GLIOMA and NEUROFIBROSARCOMA. NF1 is caused by mutations which inactivate the NF1 gene (GENES, NEUROFIBROMATOSIS 1) on chromosome 17q. The incidence of learning disabilities is also elevated in this condition. (From Adams et al., Principles of Neurology, 6th ed, pp1014-18) There is overlap of clinical features with NOONAN SYNDROME in a syndrome called neurofibromatosis-Noonan syndrome. Both the PTPN11 and NF1 gene products are involved in the SIGNAL TRANSDUCTION pathway of Ras (RAS PROTEINS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This is the first prospective follow-up study to describe the effects of oral alendronate medication on neurofibromatosis 1 (NF1)-related osteoporosis." | 9.19 | Follow-up of six patients with neurofibromatosis 1-related osteoporosis treated with alendronate for 23 months. ( Heervä, E; Huilaja, L; Leinonen, P; Peltonen, J; Peltonen, S, 2014) |
| "This is the first prospective follow-up study to describe the effects of oral alendronate medication on neurofibromatosis 1 (NF1)-related osteoporosis." | 5.19 | Follow-up of six patients with neurofibromatosis 1-related osteoporosis treated with alendronate for 23 months. ( Heervä, E; Huilaja, L; Leinonen, P; Peltonen, J; Peltonen, S, 2014) |
| "In addition, persons with high bone resorption in vitro on average had high levels of serum CTX." | 1.38 | Osteoclasts derived from patients with neurofibromatosis 1 (NF1) display insensitivity to bisphosphonates in vitro. ( Aro, HT; Heervä, E; Peltonen, J; Peltonen, S; Svedström, E; Väänänen, K, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Heervä, E | 2 |
| Huilaja, L | 1 |
| Leinonen, P | 1 |
| Peltonen, S | 2 |
| Peltonen, J | 2 |
| Svedström, E | 1 |
| Aro, HT | 1 |
| Väänänen, K | 1 |
1 trial available for alendronate and Neurofibromatosis 1
| Article | Year |
|---|---|
Follow-up of six patients with neurofibromatosis 1-related osteoporosis treated with alendronate for 23 months.
Topics: Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Female; F | 2014 |
1 other study available for alendronate and Neurofibromatosis 1
| Article | Year |
|---|---|
Osteoclasts derived from patients with neurofibromatosis 1 (NF1) display insensitivity to bisphosphonates in vitro.
Topics: Adult; Aged; Alendronate; Biomarkers; Bone Density; Bone Resorption; Cells, Cultured; Clodronic Acid | 2012 |